Day One Pharma's OJEMDA Surges 172% YoY, Charts $225M-$250M Revenue Trajectory for 2026

Record Performance in 2025: OJEMDA Hits $155.4M Milestone

Day One Biopharmaceuticals Inc. (DAWN) disclosed robust preliminary financial results ahead of its appearance at the 44th Annual J.P. Morgan Healthcare Conference. The company’s flagship product OJEMDA delivered exceptional performance in 2025, capturing $155.4 million in net product revenue for the full year—a striking 172% year-over-year increase from 2024 levels. The momentum accelerated into the final quarter, with Q4 net product revenue reaching $52.8 million, translating to a sequential gain of approximately 37% from the third quarter.

This YoY expansion was driven by escalating patient demand and intensifying prescription utilization. Notably, fourth-quarter prescription volumes reached 1,394, underscoring the accelerating market adoption of OJEMDA as a treatment option in the pediatric low-grade glioma space.

2026 Outlook: Midpoint Growth of 53%

Building on its 2025 trajectory, Day One projects 2026 U.S. OJEMDA net product revenue guidance spanning $225 million to $250 million. The midpoint of this range implies a 53% year-over-year expansion, signaling the company’s confidence in sustained commercial penetration. Management’s strategic priorities center on solidifying OJEMDA’s positioning as the standard-of-care therapy in second-line pediatric low-grade glioma, with emphasis on enhancing treatment persistence and catalyzing new patient enrollment. Parallel efforts include geographic expansion through international partnership channels.

Pipeline Advancement: Multiple Catalysts on Horizon

Beyond OJEMDA’s commercial gains, Day One’s clinical development agenda remains robust. The company anticipates completing enrollment in its pivotal Phase 3 FIREFLY-2 trial for first-line pLGG during the first half of 2026, with data readout targeted for mid-2027 and potential regulatory approval in 2028.

The Emi-Le program is progressing on schedule to deliver Phase 1 clinical data by mid-2026, positioning the asset toward registration pathways. Additionally, Day One expects to unveil initial Phase 1a data for DAY301—a PTK7-targeted antibody drug conjugate—in the second half of 2026, further diversifying the company’s therapeutic portfolio.

Financial Position and Stock Performance

As of December 31, 2025, prior to the Mersana acquisition, Day One reported approximately $441.1 million in aggregate cash, cash equivalents, and short-term investments. These preliminary figures remain subject to refinement pending the company’s complete financial report, expected in February 2026.

Stock performance reflected market enthusiasm, with DAWN shares closing January 9 at $8.94 (down $0.31 or 3.35% intraday) before rebounding sharply in after-hours trading to $10.35—a gain of $1.41 or 15.77%—signaling investor optimism regarding the company’s 2026 guidance and pipeline trajectory.